← Leaderboards
Katherine Pawelczak
Nerx Biosciences, Inc.
$2,596,140
Attributed
$2,892,280
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,892,280 · 4
By mechanism
R44$2,000,000 · 1
R43$593,005 · 2
R41$299,275 · 1
Top collaborators
- John J Turchi3 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDna RepairDna DamageMalignant NeoplasmsResponseSafetyIn VitroCancer TherapyCancer CellPatient PopulationInhibitor/AntagonistDrug KineticsPathway InteractionsRepairedDna Repair PathwayBiological AvailabilityMutationLeadMalignant Neoplasm Of LungBaseChemistryCancer PatientNovel TherapeuticsSeries
Grant awards (6)
Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy$921,320
R44 · FY2025 · CA · contact PI
Targeting the DNA Damage Response sensor Replication Protein A for first inclass cancer therapy$1,078,680
R44 · FY2024 · CA · contact PI
Development of novel Ku targeted kinase inhibitors$300,000
R43 · FY2017 · CA · contact PI
A new generation of targeted therapeutics for the treatment of cancer.$49,844
R41 · FY2017 · CA · contact PI
Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering$293,005
R43 · FY2016 · GM · contact PI
Development of novel lung cancer therapeutics targeting the DNA damage response$249,431
R41 · FY2015 · CA · contact PI